Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) has issued an announcement.
Mayne Pharma Group Limited has received an extension from the Australian Securities and Investments Commission to delay its 2025 Annual General Meeting until January 2026. This extension aligns with the anticipated timeline for the company’s acquisition by Cosette Pharmaceuticals, contingent on fulfilling certain conditions, including FIRB and Court approvals. If the acquisition proceeds as planned, Mayne Pharma will not need to hold an AGM as it will have only one shareholder. The outcome of this acquisition could significantly impact Mayne Pharma’s operational structure and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$4.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company is a leader in dermatology and women’s health in the United States and offers contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has successfully developed and commercialized new oral drug delivery systems.
Average Trading Volume: 445,294
Technical Sentiment Signal: Sell
Current Market Cap: A$394M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.